Research programme: epidermolysis bullosa therapeutics - Abeona Therapeutics

Drug Profile

Research programme: epidermolysis bullosa therapeutics - Abeona Therapeutics

Alternative Names: AAV DJCOL7A1; EB-201

Latest Information Update: 17 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abeona Therapeutics
  • Developer Abeona Therapeutics; Epidermolysis Bullosa Research Partnership; Stanford University
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Epidermolysis bullosa

Most Recent Events

  • 30 Mar 2017 Abeona Therapeutics has patent protection for EB 201 in USA
  • 30 Mar 2017 Abeona Therapeutics has patents pending for AAV capsid proteins in Europe
  • 16 Aug 2016 Preclinical trials in Epidermolysis bullosa in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top